Urological Research

, Volume 11, Issue 4, pp 159–162 | Cite as

Flow-cytophotometric studies on urine sediments of patients treated with anti-cancer-drugs

  • H. W. Schwabe
  • H.-D. Adolphs
  • J. Hartlapp


Urine specimens of 24 patients receiving polychemotherapy for malignancies of the gonads were examined by flow cytophotometry (FCM) and routine cytology. The results show abnormal DNA histograms during chemotherapy due to an arrest of the cell cycle at the S-and G2M level. In treatment protocols with ifosfamide leucocyturia develops. No cytological changes of the urothelial cells occur during treatment. All these alterations are completely reversible within 4 weeks. It is concluded that the measurable nuclear changes of urothelial cells may serve as parameters for cellular events during polychemotherapy.

Key words

Polychemotherapy Flow cytophotometry Cytology Cyclophosphamide Cell cycle Urothelial cells 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Ansell ID, Castro JE (1975) Carcinoma of the bladder complicating cyclophosphamide therapy. Br J Urol 47:431–418Google Scholar
  2. 2.
    Barlogie B, Drewinko B, Schumann J, Freireich EJ (1976) Pulse cytophotometric analysis of cell cycle pertubation with Bleomycin in vitro. Cancer Res 36:1182–1187Google Scholar
  3. 3.
    Barlogie B, Drewinko B, Benjamin RS, Freireich EJ (1976) Kinetic response of human lymphoid cells to Adrimycin-DNA complex in vitro. Cancer Res 36:2450–2454Google Scholar
  4. 4.
    Barlogie B, Drewinko B (1978) Cell cycle stage dependent induction of G2 phase arrest by different antitumor agents. European Press, Ghent, Belgium; Pulse-Cytophotometry, Part III:545–551Google Scholar
  5. 5.
    Barranco SC, Townsend CT, Costanzi JJ, Guseman LF (1982) Kinetics-directed drug treatment schedules in human tumours in vivo. Wheeless L, Goerttler K, Ploem JS, Schloss Elmau, Mittenwald Bavaria FRG, Abst Comb Int Conf Anal Cyt Cytom IX, VIth Int Symp flowcytom, p 10Google Scholar
  6. 6.
    Brock N (1980) The development of mesna for the inhibition of urotoxic side effects of Cyclophosphamide, Ifosfamide, and other oxataphosphorine cytostatics. Cancer Chemo-and Immunopharmacology, 1. Chemopharmacology. Springer, Berlin Heidelberg New York, pp 270–278Google Scholar
  7. 7.
    Büchner T, Hiddeman W (1978) Kinetic response to antileukemic drugs. European Press, Ghent, Belgium; Pulse-Cytophotometry, Part III:637–641Google Scholar
  8. 8.
    Büchner T, Hiddeman W, Wörmann B, Göhde W, Schumann J (1983) Flow cytometry and cell kinetics during treatment of human acute leukemias.-Kinetic manipulations of leukemic cells by cytosine-arabinoside (ARA-C) in correlation to therapeutic response. Leukemia Res (in press)Google Scholar
  9. 9.
    Burkert H, Schnitker J, Fichtner E (1979) Verhütung der Harnwegstoxizität von Oxazaphosphorinen durch einen Uroprotektor. Münch Med Wochenschr 121:760–762Google Scholar
  10. 10.
    D'Angio GJ, Meadows A, Miké V, Harris C, Evans A, Jaffe N, Newton W, Schweisguth O, Sutow W, Morris-Jones P (1976) Decreased risk of radiation-associated second malignant neoplasms in Actinomycin-D-treated patients. Cancer 37:1177–1185Google Scholar
  11. 11.
    Fairchild WV, Spence CR, Soloman HD, Gangai MP (1979) The incidence of bladder cancer after cyclophosphamide therapy. J Urol 122:163Google Scholar
  12. 12.
    Falck K, Gröhn P, Sorsa M, Vainio H, Heinonen E, Holsti LR (1979) Mutagenicity in urine of nurses handling cytostatic drugs. Lancet 6:1250–1251Google Scholar
  13. 13.
    Fuchs EF, Kay R, Poole R, Barry JM, Pearse HD (1981) Uroepithelial carcinoma in association with cyclophosphamide ingestion. J Urol 126:544–548Google Scholar
  14. 14.
    Gustafson H, Tribukait B, Esposti PL (1982) DNA profile and tumour progression in patients with superficial bladder tumours. Urol Res 10:13–18Google Scholar
  15. 15.
    Inoue S, Miyamoto H, Takaoka K, Araya Y (1982) Studies on effects of chemotherapeutic agents on DNA histograms of cultured human lung cancer cells using flow cytometry. Wheeless L, Goerttler K, Ploem JS, Schloss Elmau, Mittenwald Bavaria FRG, Abst Comb Int Conf Anal Cyt Cytom IX, VIth int symp flowcytom, p 98Google Scholar
  16. 16.
    Iversen OH (1978) The role of flow cytofluorometry in relation to all the other methods used in the study of cell kinetics. European Press, Ghent, Belgium; Pulse-Cytophotometry, Part III:539–544Google Scholar
  17. 17.
    Klein OH, Wickramanayake PD, Koeper CL, Christian E (1981) Experimental and clinical studies on the significance of the uroprophylactic sodium 2-mercapto-ethane sulfonate (Uromitexan) in cytostatic therapy with oxazaphosphorines. New experience with the oxazaphosphorines with special reference to the Uroprotector Uromitexan. S Karger, Basel München Paris London New York Sydney, pp 25–39Google Scholar
  18. 18.
    Li FP (1977) Second malignant tumours after cancer in childhood. Cancer 40:1899–1902Google Scholar
  19. 19.
    Muggia FM, Ziegler J (1980) Comments on the carcinogenic-mutagenic, and teratogenic properties of anticancer drugs. Cancer Chemo- and Immunopharmacology, 1. Chemo-pharmacology. Springer, Berlin Heidelberg New York, pp 306–311Google Scholar
  20. 20.
    Rao AP, Rao PN (1976) The cause of G2-arrest in chinese hamster ovary cells treated with anticancer drugs. J Natl Cancer Inst 57:1139–1143Google Scholar
  21. 21.
    Shirakawa S, Frei E (1970) Comparative effects of the antitumour agents 5-(dimethyltriazeno)-imidazole-4-car-boxamide and 1,3-bis(2-chloroethyl)-1-nitrosourea on cell cycle of L 1210 leukemia cells in vivo. Cancer Res 30:2173–2179Google Scholar
  22. 22.
    Smets LA, Mulder E, Waal FC, Cleton FJ, Blok J (1976) Early responses to chemotherapy detected by pulse cytophotometry. Br J Cancer 34:153–161Google Scholar
  23. 23.
    Spechter HJ, Bauer KM, Müller O, Traut H (1965) Folgen am harnbereitenden und harnableitenden System während Cyclophosphamid-Therapie. Dtsch Med Wocheschr 90:1458–1465Google Scholar
  24. 24.
    Schwabe HW, Adolphs HD (1982) Improved application of impulse cytophotometry for the diagnosis of urinary bladder carcinoma. Urol Res 10:61–66Google Scholar
  25. 25.
    Thorud E, Clausen OPF (1978) The effect of bleomycin on murine epidermal cell kinetics. European Press, Ghent, Belgium; Pulse-Cytophotometry; Part III:553–560Google Scholar
  26. 26.
    Tribukait B, Gustafson H (1980) Impulszytophotometrische DNS Untersuchungen bei Blasenkarzinomen. Onkologie 6: 278–288Google Scholar
  27. 27.
    Wall RL, Clausen KP (1975) Carcinoma of the urinary bladder in patients receiving cyclophoshamide. N Engl J Med 7:271–273Google Scholar

Copyright information

© Springer-Verlag 1983

Authors and Affiliations

  • H. W. Schwabe
    • 1
  • H.-D. Adolphs
    • 1
  • J. Hartlapp
    • 2
  1. 1.Department of UrologyUniversity Hospital BonnFRG
  2. 2.Department of MedicineUniversity Hospital BonnFRG

Personalised recommendations